223 related articles for article (PubMed ID: 27057630)
1. Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides.
Wei SJ; Chee S; Yurlova L; Lane D; Verma C; Brown C; Ghadessy F
Oncotarget; 2016 May; 7(22):32232-46. PubMed ID: 27057630
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of nutlin-resistant HDM2 mutants by stapled peptides.
Wei SJ; Joseph T; Chee S; Li L; Yurlova L; Zolghadr K; Brown C; Lane D; Verma C; Ghadessy F
PLoS One; 2013; 8(11):e81068. PubMed ID: 24278380
[TBL] [Abstract][Full Text] [Related]
3. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
4. Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
Chee SM; Wongsantichon J; Soo Tng Q; Robinson R; Joseph TL; Verma C; Lane DP; Brown CJ; Ghadessy FJ
PLoS One; 2014; 9(8):e104914. PubMed ID: 25115702
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Structural Determinant for Selective Targeting of HDMX.
Ben-Nun Y; Seo HS; Harvey EP; Hauseman ZJ; Wales TE; Newman CE; Cathcart AM; Engen JR; Dhe-Paganon S; Walensky LD
Structure; 2020 Jul; 28(7):847-857.e5. PubMed ID: 32359398
[TBL] [Abstract][Full Text] [Related]
6. Peptide activators of the p53 tumor suppressor.
Zhan C; Lu W
Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
[TBL] [Abstract][Full Text] [Related]
7. In vitro selection of mutant HDM2 resistant to Nutlin inhibition.
Wei SJ; Joseph T; Sim AY; Yurlova L; Zolghadr K; Lane D; Verma C; Ghadessy F
PLoS One; 2013; 8(4):e62564. PubMed ID: 23653682
[TBL] [Abstract][Full Text] [Related]
8. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
9. Effect of linker on the binding free energy of stapled p53/HDM2 complex.
Im H; Ham S
PLoS One; 2020; 15(4):e0232613. PubMed ID: 32353067
[TBL] [Abstract][Full Text] [Related]
10. hDM2 protein-binding peptides screened from stapled α-helical peptide phage display libraries with different types of staple linkers.
Anananuchatkul T; Tsutsumi H; Miki T; Mihara H
Bioorg Med Chem Lett; 2020 Dec; 30(23):127605. PubMed ID: 33038548
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Patel S; Player MR
Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma.
Jung J; Lee JS; Dickson MA; Schwartz GK; Le Cesne A; Varga A; Bahleda R; Wagner AJ; Choy E; de Jonge MJ; Light M; Rowley S; Macé S; Watters J
Nat Commun; 2016 Aug; 7():12609. PubMed ID: 27576846
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting.
Wachter F; Morgan AM; Godes M; Mourtada R; Bird GH; Walensky LD
Oncogene; 2017 Apr; 36(15):2184-2190. PubMed ID: 27721413
[TBL] [Abstract][Full Text] [Related]
14. Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.
Datta S; Bucks ME; Koley D; Lim PX; Savinov SN
Bioorg Med Chem; 2010 Aug; 18(16):6099-108. PubMed ID: 20638853
[TBL] [Abstract][Full Text] [Related]
15. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
[TBL] [Abstract][Full Text] [Related]
18. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide.
Ji Y; Majumder S; Millard M; Borra R; Bi T; Elnagar AY; Neamati N; Shekhtman A; Camarero JA
J Am Chem Soc; 2013 Aug; 135(31):11623-11633. PubMed ID: 23848581
[TBL] [Abstract][Full Text] [Related]
19. Network perspectives on HDM2 inhibitor chemotherapy combinations.
Azmi AS; Beck FW; Sarkar FH; Mohammad RM
Curr Pharm Des; 2011; 17(6):640-52. PubMed ID: 21391913
[TBL] [Abstract][Full Text] [Related]
20. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
